Dr. Seth B. Forman, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 743
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
FL license ME96509 -
Dermatopathology Physician
FL license ME96509 -
Procedural Dermatology Physician
FL license ME96509
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 743
- Services billed
- 5,590
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,887 | 298 |
| Established patient office or other outpatient visit, 20-29 minutes | 931 | 633 |
| Destruction of precancer skin growth, 1 growth | 554 | 369 |
| Biopsy of related skin growth, first growth | 216 | 185 |
| Destruction of skin growth, 1-14 growths | 179 | 166 |
| Established patient office or other outpatient visit, 30-39 minutes | 149 | 107 |
| Established patient office or other outpatient visit, 10-19 minutes | 109 | 98 |
| New patient office or other outpatient visit, 30-44 minutes | 82 | 82 |
| Biopsy of related skin growth, each additional growth | 81 | 55 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 45 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clobetasol Propionate Other prescribers in Tampa, FL | 147 |
| Triamcinolone Acetonide Other prescribers in Tampa, FL | 137 |
| Minocycline Hcl Other prescribers in Tampa, FL | 92 |
| Fluorouracil Other prescribers in Tampa, FL | 50 |
| Ketoconazole Other prescribers in Tampa, FL | 36 |
| Bimzelx Autoinjector (bimekizumab-bkzx) | 34 |
| Dupixent Pen (dupilumab) Other prescribers in Tampa, FL | 31 |
| Doxycycline Hyclate Other prescribers in Tampa, FL | 29 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Tampa, FL | 28 |
| Prednisone Other prescribers in Tampa, FL | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 85 payments worth $1,716 in total to this clinician.
| UCB, Inc. | $255 |
|---|---|
| Lilly USA, LLC | $159 |
| Pfizer Inc. | $145 |
| AbbVie Inc. | $135 |
| E.r. Squibb & Sons, L.l.c. | $135 |
| Arcutis Biotherapeutics, Inc. | $111 |
| Genzyme Corporation | $96.57 |
| Novartis Pharmaceuticals Corporation | $71.96 |
| Food and Beverage | $1,716 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 37 industry-funded studies in 2025, from 15 companies. The companies reported $1,678,397 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Eli Lilly and Company · Completed · NCT06046729 - TRIPHA TRN-228-302_Bunion_P3
Tris Pharma Inc - A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
Incyte Corporation - A phase 3 randomized withdrawal and doseup titration multicenter extension study investigating the safety efficacy and tolerability of ritlecitinib in adult and adolescent participants with nonsegmental vitiligo
Pfizer Inc. - A phase 2 randomized doubleblind placebocontrolled study to investigate the efficacy and safety of PF07275315 and PF07264660 in adult participants with moderatesevere atopic dermatitis
Pfizer Inc. - A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
Sanofi US Services Inc. · Completed · NCT05849922 - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Mod…
Janssen Research & Development, LLC - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderat…
Janssen Research & Development, LLC - A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.